Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD). Hives (also called urticaria) refer to raised and splotchy areas of skin that can be caused by an allergic reaction. 14 of 15 study participants (93%) enrolled in both dose cohorts (n=15) achieved a clinical response within the 6-week preliminary ...